Why Many Doctors Now Believe Metastatic Breast Cancer Should Be Treated as a Manageable Chronic Condition

For decades, a diagnosis of metastatic breast cancer—the stage when cancer spreads beyond the breast to distant parts of the body—was often accompanied by a grim prognosis. Survival was measured in months or a few short years, and treatment offered more burden than benefit.

Fast forward to 2025, and the prognosis has shifted dramatically. Women with metastatic breast cancer are not just surviving longer—they’re thriving, building careers, raising families, running marathons, traveling and sometimes marking 10 years or more since their diagnosis.

Related Story

Your Breast Cancer Treatment Should Work for You, Not Just Your Cancer

The change isn’t a miracle cure. Instead, it’s the cumulative result of new drugs, improved surveillance and a reimagined philosophy of care. Many oncologists now describe metastatic breast cancer as a manageable chronic disease, closer in spirit to conditions like diabetes or heart disease than the uniformly terminal illness it was once considered.

“It’s an exciting time with lots of progress,” says Dr. James Hamrick, chairman of the Caris Life Sciences Precision Oncology board. “We now have far more treatment options than we did just a decade ago—and they’re making a meaningful difference in the health and quality of life for people living with metastatic breast cancer.”

From Fatalism to Function

A generation ago, oncologists had little to offer women with metastatic breast cancer beyond a handful of standard therapies, and survival beyond three to five years was uncommon. “Ten years ago, metastatic breast cancer was largely viewed as an illness where options were limited and benefits were often short-term,” explains Dr. Wade Smith, a breast cancer oncologist at City of Hope in Newport Beach, California.

That picture began to change in the early 2000s, as researchers uncovered the biological underpinnings of different breast cancer subtypes. Those discoveries opened the door to more tailored approaches that could target the disease in new and more effective ways. In recent years, advances in understanding the immune system and in mapping the genetic drivers of tumors have further expanded the options available to patients.

“With metastatic breast cancer, we now have approaches that allow us to be much more precise in how we manage the disease, and we have far more tools in our arsenal than ever before,” explains Dr. Iman Doostan, an oncologist with Memorial Hermann Cancer Center and UTHealth Houston.

The results are measurable. A study in Cancer Epidemiology, Biomarkers & Prevention found that one in five women with metastatic breast cancer were living more than a decade after diagnosis—a once unimaginable outcome.

Marianne Matzo, PhD, the education director at Everyone Dies, a non-profit that provides public education regarding serious illness, dying, death and bereavement, says this longevity requires a cultural shift. “The perception change is one of seeing women with metastatic breast cancer as cancer survivors in need of ongoing care and surveillance rather than women for whom we have very little to offer,” she says.

A New Kind of Partnership

This evolution has redefined the doctor–patient relationship. Where care once felt like a sprint, focused on squeezing out short-term gains, it is now managed more like a marathon—one that requires strategy, pacing and collaboration.

“It changes the mindset,” says Smith. “We’re not just thinking about the next line of therapy, but how today’s decisions will affect future options. That perspective encourages ongoing monitoring and adapting as the disease, and the patient’s life changes.”

Doostan agrees, noting that the longevity afforded by new therapies allows deeper, more enduring bonds between oncologists and patients. “In the past, options were limited, and as the disease progressed, many patients would unfortunately enter hospice or pass away,” he notes. “But today, with these therapies, we can continue treating patients, which fosters a stronger, longer-term relationship.”

Shared decision-making is now central to metastatic care. Doctors weigh not only which drug to prescribe but how treatment aligns with personal goals: preserving fertility, seeing children graduate, sustaining careers or simply feeling well enough to travel.

“The conversations are very different, and much more hopeful,” says Hamrick. “Doctors spend more time talking about ‘normal life’ and longer-term goals than ever before, because people are living longer with this disease.”

Still, uncertainty remains.

Patients often struggle to plan around a disease that can shift suddenly.

“They don’t know when there will be further metastasis, whether there will be another drug available to them, and how long they will be able to do the things that are important to them,” explains Matzo. That uncertainty, she adds, makes empathy as vital as expertise. “What we need to communicate is that they are not alone in facing this disease, we are together, and that whatever comes, we’ll figure it out and deal with it.”

Beyond Medicine

As survival stretches, treatment plans must account for far more than scans and prescriptions. Survivorship now includes mental health, lifestyle choices and long-term side effect management.

“Life beyond the medications is so important,” says Hamrick. “There is almost always an initial period of shock and grief, but as that is processed life can actually become gloriously mundane again. Just like before, it’s very important to establish and maintain a healthy routine: eat well, sleep well and be active.”

Doostan takes a holistic approach, emphasizing not only physical health but also emotional and spiritual well-being. “I recommend a balanced diet and regular exercise to help patients tolerate treatment better,” he says. “I also encourage them to seek support from palliative care for pain management or a psychosocial team for emotional support. I always include these elements in my treatment approach.”

Supportive care, once synonymous with end-of-life, is now integrated early. Palliative specialists help patients manage fatigue, neuropathy or anxiety—side effects that may last for years. “We encourage exercise, nutrition, stress management and social support,” said Smith. “These are just as important as the medical treatments in helping patients live fully.”

The challenges, however, are not insignificant. Patients often cycle through multiple therapies, each with unique toxicities. Some live with the gnawing fear of running out of options. And while the science has advanced, access remains uneven. Cutting-edge therapies carry staggering costs and may not be available outside major cancer centers.

Looking Ahead

Not every patient benefits equally from this new era of treatment. Subtypes like triple-negative breast cancer remain stubbornly aggressive, and outcomes can vary widely. Still, the overall trajectory is unmistakable: More therapies are in development, survival times are stretching longer and care models are beginning to reflect not just the science but the lived experience of patients.

Survivorship itself is part of that shift. Fifty years ago, only a small fraction of Americans could call themselves cancer survivors; today that number has multiplied to nearly 19 million, with projections suggesting more than 22 million by 2035. The growth reflects progress in both detection and treatment, but also in long-term follow-up and ongoing support.

That support, many clinicians say, has changed the tenor of the doctor-patient relationship. Oncologists are increasingly focused not only on extending life but also on preserving normalcy—helping patients keep working, traveling and raising families even while managing a chronic illness. The goal is no longer limited to survival alone; it’s about enabling a good quality of life.

Hope has become a central part of that equation. Physicians describe it as both a psychological anchor and a clinical strategy. That promise of “next steps” helps patients live with less fear and more stability in the day-to-day.

The field is not yet at the point of a cure, doctors caution, but the ability to offer longer, better lives is transformative. And for many patients, the message that matters most is not about the science at all—it’s about presence.